Invesaro

Stocks Health care PLSH

OTC · Health care

Panacea Life Sciences Holdings, Inc. (PLSH)

Panacea Life Sciences Holdings, Inc. brought in $2.8M of revenue over the twelve months to March 31, 2024, up 50.4% from a year earlier. It posted a net loss of $7.7M. In fiscal 2023 capital spending exceeded operating cash flow by $1.6M. At March 31, 2024 it held $107.6K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on May 6, 2024.

Watch PLSH in 60 seconds
Price
$0.08
+2.34% on the day · September 25, 2026
52-week range $0.02 to $0.20
Market cap
$1.4M
Revenue (last 12 months)
$2.8M
+50.4% year on year
Net margin
-277.5%

What Panacea Life Sciences Holdings, Inc. does

Panacea Life Sciences Holdings, Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker PLSH.

Revenue and profit by year

Revenue
FY16: $0 $0 FY16FY17: $0 $0 FY17FY18: $0 $0 FY18FY19: $345.7K $345.7K FY19FY20: $9M $9M FY20FY21: $2.1M $2.1M FY21FY22: $1.6M $1.6M FY22FY23: $2.4M $2.4M FY23
Net income
FY16: -$1.6M -$1.6M FY16FY17: -$3.9M -$3.9M FY17FY18: -$4.3M -$4.3M FY18FY19: -$10M -$10M FY19FY20: -$5.2M -$5.2M FY20FY21: -$4.8M -$4.8M FY21FY22: -$9.1M -$9.1M FY22FY23: -$8M -$8M FY23

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2023$2.4M-$5.5M-$8M-$0.48-$1.6M
2022$1.6M-$5.7M-$9.1M-$0.62-$2.6M
2021$2.1M-$5.9M-$4.8M-$0.27-$4.1M
2020$9M-$5.3M-$5.2M-$0.31-$10.8M
2019$345.7K-$10.7M-$10M-$0.42-$6.3M
2018$0-$2.4M-$4.3M-$1.28-$465.8K

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Panacea Life Sciences Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. May 9, 2025
  2. July 16, 2024
  3. June 11, 2024
  4. May 16, 2024
  5. May 7, 2024
  6. May 6, 2024
    Quarterly report 10-Q · period to March 31, 2024Revenue rose 56% to $1.1M versus the same quarter last year; diluted EPS -$0.09 versus -$0.12.
  7. April 1, 2024
    Annual report 10-K · period to December 31, 2023Revenue rose 47% to $2.4M versus the prior year; diluted EPS -$0.48 versus -$0.62.
  8. March 7, 2024
  9. February 5, 2024
  10. December 8, 2023

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 20, 2023. Insider transactions on SEC

All filings on SEC EDGAR

Questions about PLSH

What does Panacea Life Sciences Holdings, Inc. do?

Panacea Life Sciences Holdings, Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker PLSH.

Is Panacea Life Sciences Holdings, Inc. profitable?

No. Over the twelve months to March 31, 2024 it reported a net loss of $7.7M on revenue of $2.8M.

How much revenue does Panacea Life Sciences Holdings, Inc. make?

Over the twelve months to March 31, 2024 Panacea Life Sciences Holdings, Inc. reported revenue of $2.8M. That is 50.4% more than a year earlier.

When did Panacea Life Sciences Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on May 6, 2024. It covers the period to March 31, 2024. Its newest filing of any kind is the form SEC STAFF ACTION filing from May 9, 2025.

Similar companies

Compare PLSH with

Compare PLSH with any company

Follow PLSH

Get an email when Panacea Life Sciences Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PLSH: get an email when it files

Where the numbers come from

Financial figures are the values Panacea Life Sciences Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.